Introduction Effective H1 coil stimulation for depression requires a dosage of 120% of the resting MT. However, some patients have high MTs and difficulty tolerating the high intensity that follows. ...Read More
This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
Authors: A Tendler, E Sisko, N Rodriguez, S Corbett-Methot, J Sutton-DeBord, J Brown, N Williams
Depressed, suicidal patients who failed pharmacologic and brain stimulation protocols have significant hopelessness about future treatment, making a four-week treatment protocol particularly challenging. We treated this challenging population with accelerated intermittent theta burst (iTBS) to the left PFC (L-PFC) and dorsomedial prefrontal cortex-anterior cingulate cortex (dmPFC-ACC), two regions associated with antidepressant deep rTMS(dTMS) response.
Seven severely depressed, suicidal patients, who failed pharmacotherapy and a course of dTMS, were given 108,000 pulses over three to four days. dTMS was administered at 30-50HZ in 3 pulse bursts, 10 bursts over two seconds (5HZ), followed by a five second interval, for 60 cycles (1800P over 7 minutes) with the H1 coil over the L-PFC at 90% resting hand MT followed by the H7 over the dmPFC-ACC at 90% resting foot MT. After 15-minutes from the end of H1 treatment, the cycle was repeated 10 times per day for three days. Progress was assessed with the SSI, IDS, and CGI-S at baseline and later time points. Significance was evaluated with paired t-tests.
90%MT sequential dual-target accelerated iTBS was well tolerated with headaches, jaw movements and scalp discomfort as adverse events. By day ten, suicidality decreased in 7/7 patients (Mean % decrease SSI¼21.97% ± SD¼25.61). The five patients’ depression responded and the two were non-responders by IDS-SR30 (Mean % decrease IDS-SR30¼56.02% ± SD¼21.96) and CGI-S criteria (Mean decrease CGI-S¼3.57 ± SD¼2.23). The two non-responders only tolerated 80%MT iTBS.
Accelerated sequential L-PFC, dmPFC-ACC 90%MT iTBS appears safe and helpful for suicidal patients. Controlled studies are warranted.